Cobalamin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Cobalamin
DrugBank Accession Number
DB14098
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 1329.37
Monoisotopic: 1328.564326
Chemical Formula
C62H88CoN13O14P
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
RanitidineRanitidine can cause a decrease in the absorption of Cobalamin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Biopar delta-FORTECobalamin (50 ug/1) + Cobamamide (50 ug/1) + Dihydrofolic Acid (1 mg/1) + Gastric intrinsic factor (50 mg/1) + Levoleucovorin (2.5 mg/1) + Levomefolate magnesium (7 mg/1)CapsuleOralJaymac Pharma2023-06-01Not applicableUS flag
DialyviteCobalamin (6 ug/1) + Ascorbic acid (100 mg/1) + Biotin (300 ug/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (10 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1)Tablet, coatedOralAtlantic Biologicals Corps.1988-08-01Not applicableUS flag
DialyviteCobalamin (6 ug/1) + Ascorbic acid (100 mg/1) + Biotin (300 ug/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (10 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1)Tablet, coatedOralHillestad Pharmaceuticals Usa1988-08-01Not applicableUS flag
DialyviteCobalamin (6 ug/1) + Ascorbic acid (100 mg/1) + Biotin (300 ug/1) + Folic acid (1 mg/1) + Nicotinamide (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (10 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1)Tablet, coatedOralCarilion Materials Management1988-08-01Not applicableUS flag
Dialyvite 3000Cobalamin (1 mg/1) + Ascorbic acid (100 mg/1) + Biotin (300 ug/1) + Folic acid (3 mg/1) + Nicotinamide (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (1.7 mg/1) + Selenocysteine (70 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc citrate (15 mg/1) + alpha-Tocopherol succinate (30 [iU]/1)Tablet, coatedOralHillestad Pharmaceuticals Usa2004-02-01Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
8406EY2OQA
CAS number
13408-78-1
InChI Key
ASARMUCNOOHMLO-WLORSUFZSA-L
InChI
InChI=1S/C62H90N13O14P.Co/c1-29-20-39-40(21-30(29)2)75(28-70-39)57-52(84)53(41(27-76)87-57)89-90(85,86)88-31(3)26-69-49(83)18-19-59(8)37(22-46(66)80)56-62(11)61(10,25-48(68)82)36(14-17-45(65)79)51(74-62)33(5)55-60(9,24-47(67)81)34(12-15-43(63)77)38(71-55)23-42-58(6,7)35(13-16-44(64)78)50(72-42)32(4)54(59)73-56;/h20-21,23,28,31,34-37,41,52-53,56-57,76,84H,12-19,22,24-27H2,1-11H3,(H15,63,64,65,66,67,68,69,71,72,73,74,77,78,79,80,81,82,83,85,86);/q;+2/p-2/t31-,34+,35+,36+,37-,41+,52+,53+,56+,57-,59+,60-,61-,62-;/m0./s1
IUPAC Name
lambda2-cobalt(2+) (1R,2R,3S,4S,6Z,8S,9S,11Z,14S,16Z,18R,19R)-4,9,14-tris(2-carbamoylethyl)-3,8,19-tris(carbamoylmethyl)-18-(2-{[(2S)-2-{[(2R,3S,4R,5S)-5-(5,6-dimethyl-1H-1,3-benzodiazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl phosphono]oxy}propyl]carbamoyl}ethyl)-2,3,6,8,13,13,16,18-octamethyl-20,21,22,23-tetraazapentacyclo[15.2.1.1^{2,5}.1^{7,10}.1^{12,15}]tricosa-5(23),6,10(22),11,15(21),16-hexaen-20-ide
SMILES
[Co++].[H]N([H])C(=O)CC[C@@H]1C2=N\C(=C(C)/C3=N[C@@](C)([C@]4([H])[N-]\C(=C(C)/C5=N/C(=C\2)/C(C)(C)[C@@H]5CCC(=O)N([H])[H])[C@](C)(CCC(=O)N([H])C[C@H](C)OP([O-])(=O)O[C@@H]2[C@@H](CO)O[C@@H]([C@@H]2O)N2C=NC5=C2C=C(C)C(C)=C5)[C@H]4CC(=O)N([H])[H])[C@@](C)(CC(=O)N([H])[H])[C@@H]3CCC(=O)N([H])[H])\[C@@]1(C)CC(=O)N([H])[H]

References

General References
Not Available
ChemSpider
34987587
Wikipedia
Cobalamin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4RecruitingTreatmentAnemia / Tumor1
3CompletedTreatmentDiabetic Neuropathies / Polyneuropathies1
2CompletedTreatmentLung Cancer / Metastatic Cancer / Non-Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentVitamin B12 Deficiency1
2, 3Unknown StatusTreatmentDrug Induced Movement Disorder, Unspecified / Schizophrenia / Stress Oxidative1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
CapsuleOral
TabletOral
Tablet, chewableOral
Capsule; kit; tablet, coatedOral
Tablet, coatedOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP2.63ALOGPS
logP-2.7Chemaxon
logS-5ALOGPS
pKa (Strongest Acidic)1.82Chemaxon
pKa (Strongest Basic)8.97Chemaxon
Physiological Charge2Chemaxon
Hydrogen Acceptor Count17Chemaxon
Hydrogen Donor Count9Chemaxon
Polar Surface Area460.05 Å2Chemaxon
Rotatable Bond Count26Chemaxon
Refractivity330.72 m3·mol-1Chemaxon
Polarizability132.57 Å3Chemaxon
Number of Rings8Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at June 18, 2018 18:53 / Updated at June 12, 2020 16:53